...
首页> 外文期刊>Scientific reports. >Modular, Antibody-free Time-Resolved LRET Kinase Assay Enabled by Quantum Dots and Tb3+-sensitizing Peptides
【24h】

Modular, Antibody-free Time-Resolved LRET Kinase Assay Enabled by Quantum Dots and Tb3+-sensitizing Peptides

机译:量子点和Tb3 +敏感肽可实现模块化,无抗体的时间分辨LRET激酶测定

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Fluorescent drug screening assays are essential for tyrosine kinase inhibitor discovery. Here we demonstrate a flexible, antibody-free TR-LRET kinase assay strategy that is enabled by the combination of streptavidin-coated quantum dot (QD) acceptors and biotinylated, Tb(3+) sensitizing peptide donors. By exploiting the spectral features of Tb(3+) and QD, and the high binding affinity of the streptavidin-biotin interaction, we achieved multiplexed detection of kinase activity in a modular fashion without requiring additional covalent labeling of each peptide substrate. This strategy is compatible with high-throughput screening, and should be adaptable to the rapidly changing workflows and targets involved in kinase inhibitor discovery.
机译:荧光药物筛选测定对于酪氨酸激酶抑制剂的发现至关重要。在这里,我们展示了一种灵活的,无抗体的TR-LRET激酶测定策略,该策略可通过链霉亲和素包被的量子点(QD)受体和生物素化的Tb(3+)敏化肽供体的结合来实现。通过利用Tb(3+)和QD的光谱特征以及链霉亲和素-生物素相互作用的高结合亲和力,我们无需模块对每个肽底物进行额外的共价标记,即可以模块化方式实现激酶活性的多重检测。该策略与高通量筛选兼容,并且应适用于快速变化的工作流程和涉及激酶抑制剂发现的靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号